Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Apiam deploys revolutionary tick and flea preventative for Australian dog owners, a major growth driver for FY25
    • News

    Apiam deploys revolutionary tick and flea preventative for Australian dog owners, a major growth driver for FY25

    Australian pet owners now have access to revolutionary tick and flea preventative with vet clinic operator Apiam Animal Health (ASX: AHX) having commenced sales of the injectable treatment which provides up to 12 months of  control of paralysis ticks and treatment and prevention from flea infestations. The new technology was developed by pharmaceuticals giant Merck

    Read More
    Public
  • Tryptamine Therapeutics’ psilocybin trials deliver pain relief to all patients
    • News

    Tryptamine Therapeutics’ psilocybin trials deliver pain relief to all patients

    With their new name to reflect the journey their patients undergo when treated with psychedelic drugs, Tryptamine Therapeutics (ASX: TYP) has confirmed that all patients suffering from fibromyalgia that took their TRP-8802 drug, an oral psilocybin formulation, demonstrated significant pain relief.  The study, conducted in collaboration with the University of Michigan (UOM), was presented at

    Read More
    Public
  • GDA toasts to growth with its core business while beer market sags
    • News

    GDA toasts to growth with its core business while beer market sags

    In a world where craft beverages are celebrated for their diversified tastes, beer remains a timeless favorite. Despite a challenging economic landscape, independent beverage company Good Drinks Australia (ASX: GDA), is brewing a positive financial performance.  GDA’s financial growth is experiencing a spike, attributed to its own brand volumes and key strategic initiatives that include

    Read More
    Public
  • Flat open expected with US markets unchanged
    • News

    Flat open expected with US markets unchanged

    The XJO is expected to open flat this morning following a subdued night of trading in the U.S. Their futures are also flat. After a strong run higher from our lows, it makes sense to see markets pause for the moment. Especially considering we have paused at the 50 day MA, and that there is

    Read More
    Public
  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank

    Shares in drug development company Actinogen Medical (ASX: ACW) have plummeted following the results release of their Phase 2a clinical trial seeking a treatment for depression which has failed to meet its primary endpoint.  In our fast-paced world, balancing a busy work schedule with life’s inevitable ups and downs can be challenging. Drugs for cognitive

    Read More
    Public
  • Bailador invests $7.7m in fitness studio management platform Hapana
    • News

    Bailador invests $7.7m in fitness studio management platform Hapana

    In a bold move to flex muscles, Bailador Technology (ASX: BTI) has invested $7.7 million in Hapana Holdings, a software platform that promises to make gyms and fitness studios as efficient as a Swiss watch—or at least, that’s the idea. Hapana offers an all-encompassing software solution for gyms and boutique fitness studios, enabling them to

    Read More
    Public
  • «
  • ‹
  • 43
  • 44
  • 45
  • 46
  • 47
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.